Furthermore, the cell cycle distribution results revealed that HMGB1 or BECN1 knockdown increased G0G1-phase arrest, whereas Tat-BECN1 treatment significantly decreased the percentage of G0G1-phase HMGB1-depleted CRC cells (Figures 6D; Supplementary Figure S5A). The gene discussed is TAT; the disease is colorectal carcinoma.